close
close

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Gave a “Buy” Consensus Rating by Analysts

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Gave a “Buy” Consensus Rating by Analysts


Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNMGet a Free Report) has a consensus recommendation of “Buy” from the six rating agencies currently tracking the stock, Market breakout reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts who have reported on the stock in the last year is $25.60.

A number of equity research analysts have recently expressed their views on the company. StockNews.com Actinium Pharmaceuticals was upgraded from a “sell” rating to a “hold” rating in a report on Sunday, May 5th. Stephens covered Actinium Pharmaceuticals in a report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price for the company. HC Wainwright reaffirmed their “buy” rating and set a $50.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, June 17th. Maxim Group raised their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Actinium Pharmaceuticals and set a $21.00 target price in a research note on Tuesday, April 30th.

Get Our Latest Report on Actinium Pharmaceuticals

Institutional Entries and Exits

Several institutional investors and hedge funds recently changed their holdings in ATNM. Sanders Morris Harris LLC purchased a new position in shares of Actinium Pharmaceuticals in the first quarter worth about $78,000. Creative Financial Designs Inc. ADV increased its position in Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Virtu Financial LLC increased its position in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company worth $642,000 after purchasing an additional 62,459 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotech company’s stock worth $11,325,000 after purchasing an additional 82,113 shares in the last quarter. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Shares Drop 3.3%

Actinium Pharmaceuticals stock It opened at $6.98 on Wednesday. The company has a market cap of $207.86 million, a P/E ratio of -4.08 and a beta of 0.20. Actinium Pharmaceuticals has a one-year low of $4.00 and a one-year high of $10.24.

Actinium Drugs (NYSEAMERICAN:ATNMGet a Free Report) released its latest earnings results on Friday, April 26. The biotechnology company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.11. On average, equities research analysts predict that Actinium Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Actinium Pharmaceuticals Company Profile

(Get a Free Report

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is developing targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate is I-131 apamistamab (Iomab-B), which is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with Memorial Sloan Kettering Cancer Center of a CD19-targeted CAR T cell therapy.

Selected Articles



Get News and Ratings for Actinium Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Actinium Pharmaceuticals and related companies and sign up for MarketBeat.com’s FREE daily email newsletter.